Trial document



drksid header

  DRKS00018788

Trial Description

start of 1:1-Block title

Title

A monocenter registry study to document clinical, biological and quality of life parameters in patients with gastrointestinal tumors

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

GASTRY

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Documentation of patient data of patients with gastrointestinal tumors or unknown primary including measurement of life quality.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

A monocenter registry for documenting clinical, biological and quality of life parameters in patients with gastrointestinal tumors.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

No

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00018788
  •   2020/01/14
  •   [---]*
  •   yes
  •   Approved
  •   F-2019-066, Ethik-Kommission bei der Landesärztekammer Baden-Württemberg
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Gastrointestinal tumors
  •   CUP-SYNDROM
  •   C15-C26 -  Malignant neoplasms of digestive organs
  •   C80 -  Malignant neoplasm, without specification of site
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Documentation of clinical data including molecular diagnostic results and quality of life in patients with gastrointestinal tumors or unknown primary.
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Other
  •   Other
  •   Open (masking not used)
  •   [---]*
  •   Other
  •   Other
  •   Other
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Comparison of Overall Survival between patients who received a molecular-stratified therapy after first tumor progression at latest and patients who did not.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Comparison of PFS with molecular-stratified therapy and preceding therapy (PFS-Ratio)
- Evaluation of efficacy of therapies with pre-defined parameters
- Evaluation of Tumor board decisions
- Development of a molecular map based on NGS analyses, sub-typing of molecular signalling pathways
- Correlation between mutational status and clinical parameters resp. quality of life
- Identification of prognostic and predictive factors

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2020/01/01
  •   100
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

• Patients with advanced GI Tumor or CUP Syndrome and indication of systemic treatment
• Molecular examination indicated
• Age ≥18 Jahre
• Written informed consent

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

• Severe neurologic or psychiatric disorders which interfere with the patient's ability to provide informed consent

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • SLK-Kliniken Heilbronn GmbH
    • Am Gesundbrunnen 20-26
    • 74078  Heilbronn
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • SLK-Kliniken Heilbronn GmbH
    • Ms.  Dr. rer.nat.  Dilyana  Vladimirova 
    • Am Gesundbrunnen 20-26
    • 74078  Heilbronn
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • SLK-Kliniken Heilbronn GmbH
    • Mr.  Josef  Huber 
    • Am Gesundbrunnen 20-26
    • 74078  Heilbronn
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • SLK-Kliniken Heilbronn GmbH
    • Am Gesundbrunnen 20-26
    • 74078  Heilbronn
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.